International Reporting Mechanism for Unethical Germline Gene Editing Experiments Is Needed
By G. Owen Schaefer, Markus K. Labude, Yujia Zhu, Roger Sik-Yin Foo, Vicki Xafis,
Trends in Biotechnology
| 11. 04. 2020
The 2018 revelation of the birth of the first babies whose DNA had been edited shocked the world and was met almost instantly with condemnation from scientists, ethicists, and policymakers around the world [1] (Box 1). The news was not a shock to quite everyone, however. A recent article reveals that a large number of individuals around the world knew about the experiment, in one form or another, before the news broke internationally [2]. He Jiankui, who led the experiment, had built up an international network of collaborators for several of his biotechnology ventures and at various stages communicated progress of his experiment to international colleagues. Some now say they tried to discourage him, but none made known the ongoing experiment to the broader international community.
In this article, we argue that revealing such activities is in line with scientists’ responsibilities to uphold the integrity and trustworthiness of the scientific enterprise. However, the international context complicates the situation; it is not clear whom individuals who knew about the experiment should have approached. To fill...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...